Emcure Pharmaceuticals Limited’s initial public offering of Equity Shares to open on July 03, 2024
The company
offers up to 108,900 equity shares of face value of ₹10 each, aggregating up to
₹[●] million, for subscription by eligible employees. The company also provides
a discount of up to ₹90 per equity share to eligible employees bidding under
the Employee Reservation Portion. The Net Offer and the Offer constitute ●]%
and ●]% of the post-Offer paid-up equity share capital respectively.
The Offer
is made through the Book Building Process, following Rule 19(2)(b) of the SCRR
and Regulation 31 of the SEBI ICDR Regulations. The Company may allocate up to
50% of the Net Offer to Qualified Institutional Buyers (QIBs) proportionately,
with up to 60% allocated to Anchor Investors discretionarily. One-third of this
portion is reserved for domestic Mutual Funds, subject to valid bids received
at or above the Anchor Investor Allocation Price. If under-subscription or
non-allocation occurs, the balance Equity Shares of face value of ₹10 each will
be added to the remaining QIB Portion. 5% of the Net QIB Portion is available
for allocation proportionately to Mutual Funds, while the rest is available for
all QIBs (other than Anchor Investors) subject to valid bids received at or
above the Offer Price. A minimum of 15% of the Net Offer is available for
Non-Institutional Bidders, with one-third reserved for bidders with application
sizes of more than ₹0.20 million and up to ₹1.00 million. A minimum of 35% of
the Net Offer is available for Retail Individual Bidders.
The Red
Herring Prospectus offers Equity Shares to be listed on both BSE and NSE. Kotak
Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private
Limited, and J.P. Morgan India Private Limited are Book Running Lead Managers.
Capitalized terms in this press release have the same meaning as in the RHP.
Comments
Post a Comment